PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders

Aim. To assess the efficacy and safety of PCSK9 inhibitor alirocumab as part of a combination lipid-lowering therapy in patients with acute coronary syndrome (ACS).Material and methods. This prospective, open-label, single-center activetreatment study included 13 patients hospitalized due to ACS. Th...

ver descrição completa

Detalhes bibliográficos

Principais autores:	O. L. Barbarash, N. V. Fedorova, D. Yu. Sedykh, O. V. Gruzdeva, O. N. Khryachkova, V. V. Kashtalap, A. A. Filimonova
Formato:	Artigo
Idioma:	Russo
Publicado em:	«FIRMA «SILICEA» LLC 2020-09-01
coleção:	Российский кардиологический журнал
Assuntos:	dyslipidemia acute coronary syndrome pcsk9 inhibitors alirocumab
Acesso em linha:	https://russjcardiol.elpub.ru/jour/article/view/4010
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!